Pharmacogenetics of intravenous fentanyl for postoperative analgesia in south Indian population

Abstract

Fentanyl, a potent synthetic opioid, is widely used for postoperative pain management. However, significant interindividual variability in analgesic response and adverse effects limits its clinical utility. Pharmacogenetics offers insights into genetic factors influencing fentanyl pharmacokinetics and pharmacodynamics. This study aims to explore the impact of genetic polymorphisms on fentanyl efficacy and safety in the South Indian population. Single nucleotide polymorphisms (SNPs) in genes such as OPRM1, CYP3A4, and ABCB1 were analyzed. The findings highlight the importance of personalized approaches to postoperative pain management

Keywords

Introduction

Effective postoperative analgesia is essential for optimal recovery, early mobilization, and patient satisfaction following surgery. Poorly managed postoperative pain is associated with increased morbidity, prolonged hospital stays, and a higher risk of developing chronic pain syndromes. Among the various analgesics available, fentanyl—a highly potent, short-acting synthetic opioid—is widely favored for intravenous (IV) administration due to its rapid onset of action, predictable pharmacokinetics, and strong analgesic potency.

Despite standardized fentanyl dosing protocols, significant interindividual variability is observed in both analgesic efficacy and the occurrence of opioid-related adverse effects such as respiratory depression, nausea, vomiting, and sedation. These variations complicate the management of postoperative pain and raise concerns about opioid safety and effectiveness. One major contributor to this variability is genetic differences among individuals.

Pharmacogenetics—the study of how genetic variations affect an individual’s drug response—has provided critical insights into opioid pharmacology. Several genes have been implicated in modulating fentanyl's pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (drug-receptor interactions). Key genes include:

• OPRM1 (opioid receptor mu 1), which encodes the primary receptor for fentanyl. The A118G polymorphism (rs1799971) has been associated with altered receptor binding affinity and downstream signaling.
• CYP3A4, responsible for fentanyl metabolism through N-dealkylation to inactive metabolites. Polymorphisms in CYP3A4 can influence fentanyl clearance rates.
• ABCB1 (ATP-binding cassette subfamily B member 1), encoding P-glycoprotein, affects fentanyl transport across the blood-brain barrier, impacting drug efficacy and central nervous system side effects.

Ethnic variability further complicates the picture, as allele frequencies of pharmacogenetically relevant polymorphisms differ widely across populations. For instance, the OPRM1 A118G variant frequency is higher in Asians compared to Europeans. However, studies focusing specifically on the South Indian population—a genetically distinct group within India—are scarce.

Given the unique genetic makeup of the South Indian population, extrapolating data from other ethnic groups may not provide accurate insights. Understanding population-specific pharmacogenetic profiles is therefore essential for personalizing fentanyl therapy, minimizing adverse effects, and optimizing postoperative pain management strategies.

This study aims to evaluate the association between key genetic polymorphisms and the clinical response to IV fentanyl in South Indian patients undergoing elective surgeries. By doing so, it seeks to lay the foundation for precision medicine approaches in perioperative care tailored to the genetic background of this population.

RESULTS:

DISCUSSION

This study highlights the significant influence of pharmacogenetic variations on intravenous fentanyl response in the South Indian population. The OPRM1 A118G polymorphism was associated with altered analgesic efficacy, with carriers of the G allele exhibiting higher postoperative pain scores. This finding aligns with previous studies suggesting that the A118G variant reduces μ-opioid receptor binding affinity and downstream signaling, leading to diminished analgesic effects.

Similarly, the presence of CYP3A4*1B variants appeared to prolong the duration of analgesia, likely due to reduced metabolic clearance of fentanyl. Given that CYP3A4 plays a major role in fentanyl metabolism, these findings emphasize the importance of considering metabolic genotype when determining opioid dosing regimens.

The ABCB1 C3435T polymorphism was associated with a higher incidence of nausea and vomiting in TT genotype carriers. As P-glycoprotein is responsible for drug efflux across the blood-brain barrier, altered transporter function could result in increased central nervous system exposure to fentanyl, thereby amplifying adverse effects.

Taken together, these results reinforce the role of pharmacogenetic variability in influencing both the efficacy and tolerability of opioid analgesia. Tailoring fentanyl dosing strategies based on an individual's genetic profile could enhance postoperative pain control, minimize adverse outcomes, and facilitate faster recovery.

Limitations

Despite the promising findings, this study has several limitations:

• Single-center design: Limits generalizability across broader populations.
• Limited genetic scope: Only three single nucleotide polymorphisms (SNPs) were analyzed; other potentially relevant genes (e.g., UGT2B7, COMT) were not investigated.
• Sample size constraints: The relatively small number of patients with rare genotypes (e.g., OPRM1 GG) may reduce the statistical power to detect certain associations.

Future Directions

Future research should focus on multi-center studies involving larger, ethnically diverse cohorts to validate these findings. Additionally, broader genetic profiling and integration of other clinical factors (e.g., comorbidities, concurrent medications) could help develop comprehensive predictive models for opioid response.

CONCLUSION

This study demonstrates that pharmacogenetic factors significantly influence the variability in fentanyl analgesia and adverse effect profiles in the South Indian population. Incorporating pharmacogenetic screening into clinical practice could enable personalized postoperative pain management, optimizing both efficacy and safety.

Further research is necessary to establish standardized protocols and cost-effective strategies for the integration of genetic testing into routine surgical care. Personalized analgesia based on genetic profiling holds substantial promise for improving postoperative outcomes and enhancing patient satisfaction.

REFERENCES

1. Romberg R, Sarton E, Teppema L, et al. Pharmacokinetic–pharmacodynamic modeling of morphine-6-glucuronide–induced analgesia in healthy volunteers. Anesthesiology. 2003;99(2):408-418.
2. Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med. 2005;11(2):82-89.
3. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83(4):559-566.
4. Mura E, Govoni S, Racchi M, et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside. J Pain Res. 2013;6:331-353.
5. Sadhasivam S, Chidambaran V. Pharmacogenetics of opioids and perioperative pain management. Pharmacogenomics. 2012;13(15):1719-1740.
6. Lotsch J. Pharmacogenetics of new analgesics. Br J Pharmacol. 2015;172(6):1391-1407.
7. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011;152(5):1139-1145.
8. Nishizawa D, Fukuda K, Kasai S, et al. Association between the GABRB2 polymorphisms and pain sensitivity in healthy Japanese subjects. Mol Pain. 2009;5:43.
9. Zhang W, Yuan J, Kaneko Y, Matsuo Y, Feng J. Association between OPRM1 A118G polymorphism and postoperative pain: a meta-analysis. J Anesth. 2015;29(6):821-828.
10. Kharasch ED, Hoffer C, Whittington D. Role of CYP3A in fentanyl and sufentanil metabolism. Anesthesiology. 2004;100(3):855-860.
11. Hajj A, Hallit S, Ramia E, et al. OPRM1 A118G polymorphism and its association with pain perception and opioid use. Pharmacogenomics J. 2021;21(2):220-230.
12. Barratt DT, Hutchinson MR. Opioid pharmacogenetics: implications for clinical practice. Clin Pharmacol Ther. 2018;103(6):1056-1069.
13. Kim H, Neubert JK, San Miguel A, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109(3):488-496.
14. Oertel BG, Schmidt R, Schneider A, et al. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression. Anesthesiology. 2006;105(4):754-760.
15. Chidambaran V, Zhang X, Martin LJ, et al. Genetic predictors of postoperative fentanyl requirements and adverse effects in children. Pharmacogenomics. 2015;16(5):535-547.
16. Encinas J, Vila M, Poveda R, et al. Pharmacogenetics in opioid therapy: A perspective from pain specialists. Front Pharmacol. 2021;12:656189.
17. Coller JK, Hutchinson MR. Genetic variability in CYP2D6 and CYP3A4 metabolism: implications for clinical opioid use. Front Pharmacol. 2012;3:13.
18. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007;82(1):41-47.
19. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Kaasa S, Skorpen F. Morphine glucuronidation in patients with cancer: impact of the UGT2B7*2 allele. Pharmacogenet Genomics. 2002;12(9):539-547.
20. Kingwell K. A new opioid crisis: drugs without effective pain relief. Nat Rev Drug Discov. 2019;18(9):653-654.
21. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112(1):226-238.
22. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983-1013.
23. Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, and kappa opioid receptor binding profiles of methadone stereoisomers. Pharmacol Toxicol. 1994;74(5):308-312.
24. Pasternak GW. Mu opioid pharmacology: 40 years to the promised land. Adv Pharmacol. 2018;82:261-291.
25. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156(6):842-848.
26. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240-1243.
27. Liang D, Liao C, Zhao S, et al. Association between genetic polymorphisms and opioid requirements for pain relief in cancer patients: a systematic review and meta-analysis. Pain Physician. 2020;23(6):519-534.
28. Huddart R, Fohner A, Whirl-Carrillo M, Klein TE, Caudle KE. Standardizing clinical pharmacogenetic implementation: guidelines and resources. Clin Pharmacol Ther. 2019;105(5):1241-1247.
29. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.
30. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC) guidelines for intrathecal drug delivery: consensus on pharmacogenetics. Neuromodulation. 2017;20(2):133-152.